Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T2347 vs Xalacom in Glaucoma and Ocular Hypertension
NCT02278614Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002), timolol in open-angle glaucoma (OAG), ocular hypertension, sponsored by Laboratoires Théa. Started Dec 2014; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02278614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278614.